For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Chikungunya virus infections - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chikungunya virus infections Understanding
Chikungunya virus infections: Overview
Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus. It was first described during an outbreak in southern Tanzania in 1952 and has now been identified in nearly 40 countries in Asia, Africa, Europe and, most recently, the Americas. Symptoms usually begin 4 to 8 days after a mosquito bite but can appear anywhere from 2 to 12 days. The most common symptom is an abrupt onset of fever, often accompanied by joint pain. Other symptoms include muscle pain, headache, nausea, fatigue, and rash. Severe joint pain usually lasts a few days but can persist for months or even years. Serious complications are uncommon, but atypical severe cases can cause long-term symptoms and even death, especially in older people.
"Chikungunya virus infections - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chikungunya virus infections pipeline landscape is provided which includes the disease overview and Chikungunya virus infections treatment guidelines. The assessment part of the report embraces, in depth Chikungunya virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chikungunya virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chikungunya virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Chikungunya virus infections.
Chikungunya virus infections Emerging Drugs Chapters
This segment of the Chikungunya virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chikungunya virus infections Emerging Drugs
- VLA1553: Valneva
VLA1553 is the chikungunya vaccine candidate in Phase 3 clinical trials that targets long-term protection following the administration of a single dose. Valneva reported positive topline results from a Phase 3 pivotal trial in August 2021. The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the U.S., met its primary endpoint inducing protective CHIKV neutralizing antibody titers in 98.5% of participants 28 days after receiving a single shot. VLA1553 was also generally well tolerated among the 3,082 subjects evaluated for safety. VLA1553 has received Fast Track and Breakthrough Therapy designation from the FDA and PRIME designation from the EMA
- mRNA-1944: Moderna Therapeutics
mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against chikungunya infection. It is composed of two mRNAs that encode the heavy and light chains of this anti-chikungunya antibody within Moderna's proprietary lipid nanoparticle (LNP) technology. Currently, it is in phase I stage of clinical trial evaluation to treat Chikungunya virus infections.
Further product details are provided in the report ..
Chikungunya virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Chikungunya virus infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chikungunya virus infections
There are approx. 10+ key companies which are developing the therapies for Chikungunya virus infections. The companies which have their Chikungunya virus infections drug candidates in the most advanced stage, i.e. phase III include, Valneva.
- Phases
DelveInsight's report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Chikungunya virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chikungunya virus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chikungunya virus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chikungunya virus infections drugs.
Chikungunya virus infections Report Insights
- Chikungunya virus infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chikungunya virus infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chikungunya virus infections drugs?
- How many Chikungunya virus infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chikungunya virus infections?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chikungunya virus infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chikungunya virus infections and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Valneva
- Moderna Therapeutics
- Immunomodulation
- Ridgeback Biotherapeutics
- Etubics Corporation
- Themis Bioscience
- FIT Biotech
- Bharat Biotech
- Emergex Vaccines
- Emergent BioSolutions
- Indian Immunologicals Ltd.
- Auro Vaccines
Key Products
- VLA1553
- mRNA 1944
- Annexin A5
- Molnupiravir
- MV-CHIK
- FIT-103
- BBV 87
- VRC CHKVLP059 00 VP